Journal
CANCER LETTERS
Volume 287, Issue 2, Pages 165-171Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2009.06.008
Keywords
Dual-targeting; Drug delivery system; Liposomes; Active-targeting; Antineovascular therapy; Angiogenesis
Categories
Ask authors/readers for more resources
Dual-targeting liposomes modified with 3Ala-Pro-Arg-Pro-Gly (APRPG) and Gly-Asn-Gly-Arg-Gly (GNGRG) peptides were developed. They remarkably associated to growing human umbilical vein endothelial cells (HUVECs) compared with single-targeting liposomes modified with APRPG or GNGRG. Doxorubicin (DOX) encapsulated in the dual-targeting liposomes significantly suppressed the growth of HUVECs compared with that in single-targeting liposomes. The dual-targeting liposomes containing DOX strongly suppressed tumor growth in Colon26 NL-17 carcinoma-bearing mice. Confocal microscopic data indicated that this anticancer effect was brought by the association of these liposomes to angiogenic vessels in the tumor. These findings suggest that dual-targeting would be a hopeful method for targeting therapies. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available